

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 8-K

BIOCRYST PHARMACEUTICALS INC

Form 8-K

March 31, 2004

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: March 31, 2004

BioCryst Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

|                                                               |                                          |                                                  |
|---------------------------------------------------------------|------------------------------------------|--------------------------------------------------|
| Delaware<br>(State or other jurisdiction<br>of incorporation) | 000-23186<br>(Commission<br>File Number) | 62-1413174<br>(IRS Employer<br>Identification #) |
|---------------------------------------------------------------|------------------------------------------|--------------------------------------------------|

2190 Parkway Lake Drive, Birmingham, Alabama 35244  
(Address of Principal Executive Office)

(205) 444-4600  
(Registrant's telephone number, including area code)

Item 5. Other Events and Regulation FD Disclosure.

On March 31, 2004, Registrant issued a press release announcing the initiation of a Phase II clinical trial of BCX-1777 in T-cell leukemia. The press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K.

Neither the filing of any press release as an exhibit to this Current Report on Form 8-K nor the inclusion in such press release of a reference to Registrant's Internet address shall, under any circumstances, be deemed to incorporate the information available at such Internet address into this Current Report on Form 8-K. The information available at Registrant's Internet address is not part of this Current Report on Form 8-K or any other report filed by Registrant with the Securities and Exchange Commission.

Item 7. Exhibits.

| Exhibit No. | Description                                                                                                                              |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------|
| 99.1        | Press release dated March 31, 2004 entitled "BioCryst Pharmaceuticals Initiates Phase II Clinical Trial of BCX-1777 in T-Cell Leukemia". |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 31, 2004

BioCryst Pharmaceuticals, Inc.

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 8-K

By: /s/ Michael A. Darwin

-----  
Michael A. Darwin  
Chief Financial Officer and Chief  
Accounting Officer

EXHIBIT INDEX

| Item | Description                                                                                                                              |
|------|------------------------------------------------------------------------------------------------------------------------------------------|
| 99.1 | Press release dated March 31, 2004 entitled "BioCryst Pharmaceuticals Initiates Phase II Clinical Trial of BCX-1777 in T-Cell Leukemia". |